Coincheck Group N.V. to Announce Third Quarter 2025 Results on February 12, 2025
Coincheck Group N.V. (the “Company”) (Nasdaq: CNCK), the holding company for Coincheck, Inc, a leading Japanese crypto exchange, today announced that the Company will release its third quarter 2025 financial results on Wednesday, February 12, 2025. The Company will host a conference call to discuss third quarter 2025 financial results at 5:00 pm ET that same day. Hosting the call will be Oki Matsumoto, Executive Chairman, Gary Simanson, Chief Executive Officer, and Jason Sandberg, Chief Financial Officer.
The call will be webcast live from the Company's website at www.coincheckgroup.com. A replay will be available on the Company’s investor relations website following the call. The conference call can also be accessed over the phone by dialing (877) 407-4018 or (201) 689-8471; the Conference ID is 13751285.
About Coincheck Group N.V.
Headquartered in the Netherlands, Coincheck Group N.V. (NASDAQ: CNCK) is a public limited liability company and the holding company for Coincheck, Inc. Coincheck operates one of the largest multi-cryptocurrency marketplaces and crypto asset exchanges in Japan and is regulated by the Japan Financial Services Agency. Coincheck provides Marketplace and Exchange platforms on which diverse cryptocurrencies, including Bitcoin and Ethereum, are held and exchanged as well as other retail-focused crypto services
View source version on businesswire.com: https://www.businesswire.com/news/home/20250131399595/en/
Contacts
Media and Investor Relations Contact:
CoincheckIR@icrinc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Viromed Medical AG reaches milestone for cooperation with multinational corporation28.2.2025 21:02:00 EET | Press release
Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65) has reached a milestone in the extensive cooperation with a multinational corporation announced via ad hoc notification on 11 December 2024. The subject of the agreement now concluded is, in particular, the granting of a European license right in favour of Viromed Medical AG for the use of cold atmospheric pressure plasma in medicine. By granting the license rights, Viromed Medical AG is considered a manufacturer of ViroCAP® systems for use in dermatology within the meaning of the Medical Device Regulation (MDR). All intellectual property (IP) rights and the resulting patents and exploitation rights from the two companies' studies on the use of the PulmoPlas® system in pulmonary medicine are held solely by Viromed Medical AG. relyon plasma GmbH, a subsidiary of TDK Electronics AG, will produce both the ViroCAP® systems and the PulmoPlas® systems on behalf of Viromed Medical. The special approval by the Federal Institute for Drugs an
Canoga Perkins Launches Private 5G with TSN Demo, Showcasing a Streamlined way to Deploy Private 5G for Industrial and Enterprise Use Cases28.2.2025 20:21:00 EET | Press release
Network connectivity solutions provider, Canoga Perkins today announces the launch of its Private 5G with Time-Sensitive Networking (TSN) demonstration in its Customer Experience Center (CEC). This demo serves as a model for how Private 5G should be deployed, offering a streamlined, reliable, and secure approach for industrial and enterprise applications. The setup integrates the Moso Canopy 5GID2 radio and Canoga Perkins’ switch and transport solution, SyncMetra, creating a comprehensive, best-in-class Private 5G solution. The combination of these technologies simplifies the deployment process, reduces complexity, and ensures high performance for mission-critical applications. “Private 5G has the potential to revolutionize industrial and enterprise connectivity, but only if deployed correctly,” said Malik Arshad, CEO of Canoga Perkins. “With this demonstration, we are showcasing a proven, scalable, and secure approach that enterprises can adopt with confidence. By leveraging Moso’s hi
Venture Global, Inc. Announces Record Date for Cash Dividend28.2.2025 19:56:00 EET | Press release
The Venture Global, Inc. (“Venture Global”) (NYSE: VG) board of directors determined today that the per share amount of its previously declared cash dividend shall be $0.0165 per share, or approximately $40 million in the aggregate, payable on March 31, 2025 to holders of its outstanding Class A common stock and outstanding Class B common stock, and that the record date shall be the close of business on March 10, 2025. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. Venture Global’s first facility, Calcasieu Pass, commenced producing LNG in January 2022. The company’s second facility, Plaquemines LNG, achieved first production of LNG in December 2024. The company is currently constructing and developing over 100 MTPA of nameplate production capac
Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting28.2.2025 16:30:00 EET | Press release
Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its dermatology portfolio will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting, being held March 7–11, 2025, in Orlando. "We look forward to sharing new data for ruxolitinib cream (Opzelura®) across multiple indications, including prurigo nodularis, and axatilimab (Niktimvo™) in patients with dermatologic manifestations of chronic graft-versus-host disease (GVHD) at this year's AAD Annual Meeting,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. "Incyte’s active participation in this key congress reinforces our commitment to addressing critical needs in dermatology while fostering meaningful dialogue with researchers, patients and advocates to inform the development of innovative treatments.” Key abstracts include: Late-Breaking Oral Presentation Prurigo Nodularis (PN) Efficacy and Safety of Ruxolitinib Cream in Patients With Prurig
ENHERTU ® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy28.2.2025 15:00:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast06 phase 3 trial presented at the 2024 American Society of Clinical Oncology (#ASCO24) Annual Meeting and pu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom